デフォルト表紙
市場調査レポート
商品コード
1485241

BNP・NT-proBNPの世界市場 - 産業規模、シェア、動向、機会、予測:タイプ別、検査場所別、用途別、地域別、競合別(2019年~2029年)

BNP And NTproBNP Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, NT-proBNP, By Location of Testing, By Application, By Region and Competition, 2019-2029F

出版日: | 発行: TechSci Research | ページ情報: 英文 185 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

BNP・NT-proBNPの世界市場 - 産業規模、シェア、動向、機会、予測:タイプ別、検査場所別、用途別、地域別、競合別(2019年~2029年)
出版日: 2024年05月24日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のBNP・NT-proBNPの市場規模は、2023年に18億4,056万米ドルと評価され、2029年までのCAGRは7.25%で、予測期間中に着実な成長を予測しています。

BNP(脳性ナトリウム利尿ペプチド)とNT-proBNP(N-末端プロ脳性ナトリウム利尿ペプチド)は、医療と診断の分野、特に心臓病学と心臓関連疾患で使用されるバイオマーカーです。これらのマーカーは心臓疾患の評価と管理において重要な役割を果たしており、世界の医療市場にとって不可欠な要素となっています。

市場概要
予測期間 2025年~2029年
市場規模:2023年 18億4,056万米ドル
市場規模:2029年 27億8,544万米ドル
CAGR:2024年~2029年 7.25%
急成長セグメント ポイントオブケア検査
最大市場 北米

BNP・NT-proBNP市場は、広範な診断・医療産業の重要なセグメントです。この市場には、これらのバイオマーカーの測定、分析、活用に関する幅広い製品とサービスが含まれます。この市場は、いくつかの主要な構成要素に分けることができます。BNP・NT-proBNP市場は、世界の心血管疾患の有病率の増加により、長年にわたって着実な成長を遂げています。人口の高齢化、座りがちなライフスタイル、肥満や糖尿病などの危険因子の増加に伴い、心臓関連の問題を正確かつ早期に発見する必要性が高まっています。市場競争は激しく、世界的・地域的な企業が複数存在します。この市場に参入している主な企業には、Roche Diagnostics、Abbott Laboratories、Siemens Healthineers、Thermo Fisher Scientificなどがあります。これらの企業は、アッセイ、機器、ポイントオブケア機器など、さまざまなBNP・NT-proBNP検査ソリューションを提供しています。この分野での競合は、製品の技術革新、価格設定、医療プロバイダーとの強力なパートナーシップを確立する能力によって左右されます。

BNP・NT-proBNPマーカーは、主に心臓関連の疾患の診断とモニタリングに使用されます。心不全の評価、心不全と他の呼吸器疾患の鑑別、患者の予後予測、治療方針の決定に役立っています。個別化医療や標的治療の需要が高まるにつれて、これらのバイオマーカーは心臓病患者の治療戦略を調整する上でさらに重要になります。同市場は、技術の進歩や非侵襲的で迅速な診断法への注目の高まりにより、絶えず進化しています。これには、高感度アッセイの開発、データ解析における人工知能と機械学習の統合、より迅速で簡便な検査を可能にする携帯型ポイントオブケア機器の出現などが含まれます。遠隔医療と遠隔モニタリングの採用は、BNP・NT-proBNPマーカーの活用に新たな機会をもたらしました。BNP・NT-proBNP市場は、特に新興国市場では厳しい規制監督下にあります。例えば米国では、食品医薬品局(FDA)がこれらの診断薬の承認と販売を厳しく監視しています。規制要件の遵守と品質基準の順守は、この市場で事業を展開する企業にとって不可欠です。

市場には多くの成長機会がある一方で、コストの制約や償還の問題などの課題もあります。バイオマーカーの導入は、医療システムにおける予算の制約によって妨げられ、高度な診断検査へのアクセスが制限される可能性があります。しかし、BNP・NT-proBNP検査の臨床的有用性に対する認識が高まり、これらのマーカーが臨床ガイドラインに組み込まれることで、大きな成長の見通しが得られます。結論として、BNP・NT-proBNP市場は、心臓疾患の罹患率の上昇と正確でタイムリーな診断ソリューションへの需要に牽引され、医療および診断業界の重要な構成要素となっています。BNP・NT-proBNP市場は、幅広い製品、サービス、技術を包含しており、競合情勢は世界の大手企業によって支配されています。技術の進歩が続き、医療・システムが費用対効果の高いソリューションを求める中、BNP・NT-proBNP市場はさらなる成長と技術革新の態勢を整えており、最終的には循環器領域における患者ケアと転帰の改善に貢献します。

主な市場促進要因

心血管疾患の増加

個別化医療の動向

主な市場課題

医療システムにおけるコスト制約

代替診断法との競合

検査結果のばらつき

規制遵守と品質基準

主な市場動向

遠隔医療と遠隔モニタリング

高感度アッセイの開発

AIと機械学習の統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のBNP・NT-proBNP市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別(BNP(脳性ナトリウム利尿ペプチド)、NT-proBNP(N末端プロB型ナトリウム利尿ペプチド))
    • 検査場所別(ポイントオブケア検査、臨床検査)
    • 用途別(心筋梗塞、うっ血性心不全、急性冠症候群(ACS)、その他)
    • 地域別
    • 企業別(2023年)
  • 市場マップ
    • タイプ別
    • 検査場所別
    • 用途別
    • 地域別

第5章 アジア太平洋地域のBNP・NT-proBNP市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 検査場所別
    • 用途別
    • 国別
  • アジア太平洋:国別分析
    • 中国
    • インド
    • オーストラリア
    • 日本
    • 韓国

第6章 欧州のBNP・NT-proBNP市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 検査場所別
    • 用途別
    • 国別
  • 欧州:国別分析
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • 英国

第7章 北米のBNP・NT-proBNP市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 検査場所別
    • 用途別
    • 国別
  • 北米:国別分析
    • 米国
    • メキシコ
    • カナダ

第8章 南米のBNP・NT-proBNP市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 検査場所別
    • 用途別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第9章 中東・アフリカのBNP・NT-proBNP市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 検査場所別
    • 用途別
    • 国別
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第10章 市場力学

  • 促進要因
  • 課題

第11章 市場動向と発展

  • 最近の動向
  • 製品発売
  • 合併と買収

第12章 世界のBNP・NT-proBNP市場:SWOT分析

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Specim, Spectral Imaging Ltd
  • Gentian Diagnostics ASA
  • Siemens AG
  • PerkinElmer Inc
  • Biomerieux SA
  • Quidel Corporation
  • Bio-Rad Laboratories, Inc.
  • F. Hoffman-La Roche Ltd
  • BHR Pharmaceuticals Ltd.
  • Xiamen Biotime Biotechnology Co., Ltd.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 21020

Global BNP And NT-proBNP Market was valued at USD 1840.56 Million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 7.25% through 2029. BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) are biomarkers used in the field of healthcare and diagnostics, particularly in cardiology and heart-related conditions. These markers play a crucial role in the assessment and management of heart diseases, making them an essential component of the global healthcare market.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 1840.56 Million
Market Size 2029USD 2785.44 Million
CAGR 2024-20297.25%
Fastest Growing SegmentPoint Of Care Testing
Largest MarketNorth America

The BNP and NT-proBNP market is a vital segment of the broader diagnostic and healthcare industry. It encompasses a wide range of products and services related to the measurement, analysis, and utilization of these biomarkers. This market's description can be broken down into several key components. The BNP and NT-proBNP market has been experiencing steady growth over the years due to the increasing prevalence of cardiovascular diseases worldwide. With the aging population, sedentary lifestyles, and the rise in risk factors such as obesity and diabetes, there is a growing need for accurate and early detection of heart-related issues. The market is highly competitive, with several global and regional players. Major companies involved in this market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific, among others. These companies offer a variety of BNP and NT-proBNP testing solutions, including assays, instruments, and point-of-care devices. The competition in this sector is driven by product innovation, pricing, and the ability to establish strong partnerships with healthcare providers.

BNP and NT-proBNP markers are primarily used in diagnosing and monitoring heart-related conditions. They are instrumental in assessing heart failure, distinguishing between heart failure and other respiratory disorders, predicting patient outcomes, and guiding treatment decisions. As the demand for personalized medicine and targeted therapies grows, these biomarkers become even more critical in tailoring treatment strategies for heart patients. The market is continually evolving, driven by technological advancements and a growing focus on non-invasive and rapid diagnostic methods. This includes the development of high-sensitivity assays, integration of artificial intelligence and machine learning in data analysis, and the emergence of portable point-of-care devices that enable quicker and more convenient testing. The adoption of telemedicine and remote monitoring has opened new opportunities for the utilization of BNP and NT-proBNP markers. The BNP and NT-proBNP market is subject to stringent regulatory oversight, particularly in developed regions. In the United States, for instance, the Food and Drug Administration (FDA) closely monitors the approval and marketing of these diagnostic products. Compliance with regulatory requirements and adherence to quality standards are essential for companies operating in this market.

While the market presents numerous growth opportunities, it also faces challenges, such as cost constraints and reimbursement issues. The adoption of these biomarkers can be hindered by budget constraints in healthcare systems, which may limit access to advanced diagnostic tests. However, the increasing awareness of the clinical benefits of BNP and NT-proBNP testing and the incorporation of these markers into clinical guidelines provide significant growth prospects. In conclusion, the BNP and NT-proBNP market is a crucial component of the healthcare and diagnostics industry, driven by the rising incidence of heart diseases and the demand for accurate and timely diagnostic solutions. It encompasses a wide range of products, services, and technologies, with a competitive landscape dominated by leading global companies. As technology continues to advance and healthcare systems seek cost-effective solutions, the BNP and NT-proBNP market is poised for further growth and innovation, ultimately contributing to improved patient care and outcomes in the field of cardiology.

Key Market Drivers

Increasing cardiovascular diseases

The increasing prevalence of cardiovascular diseases is a significant driver of the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market. Cardiovascular diseases, including heart failure, coronary artery disease, and hypertension, have reached epidemic proportions globally. This surge in heart-related conditions is attributed to several factors, which in turn fuel the demand for BNP and NT-proBNP testing. Firstly, the aging population is a major contributor to the rise in cardiovascular diseases.

As the world's population continues to age, there is a higher incidence of heart-related conditions, particularly heart failure, which becomes more prevalent with advancing age. This demographic shift places an increasing burden on healthcare systems, making early and accurate diagnosis of heart diseases crucial. Lifestyle changes and risk factors such as obesity, sedentary lifestyles, and unhealthy dietary habits have become more widespread. These factors significantly contribute to the development of heart diseases, making proactive screening and monitoring of cardiac health essential. The growing awareness of the importance of cardiovascular health has led to increased screening and early detection efforts. As patients and healthcare providers recognize the need for timely diagnosis, BNP and NT-proBNP testing become critical tools for identifying heart conditions in their early stages. This awareness has led to a surge in the demand for diagnostic testing, further driving market growth.

The complexity of cardiovascular diseases and the need for precision medicine have led to a more personalized approach to patient care. BNP and NT-proBNP markers play a pivotal role in tailoring treatment strategies, guiding therapy decisions, and assessing prognosis. Their ability to provide accurate insights into the patient's cardiac status positions them as indispensable tools in the management of heart diseases. In recent years, the healthcare landscape has been transformed by the adoption of telemedicine and remote patient monitoring. These technologies enable patients to receive cardiac assessments and monitoring without frequent in-person visits, making BNP and NT-proBNP testing even more relevant. Healthcare providers can remotely track patients' cardiac health, ensuring early intervention when necessary. Regulatory bodies and clinical guidelines increasingly endorse the use of BNP and NT-proBNP markers in heart disease management. This official support enhances the credibility and adoption of these biomarkers in clinical practice, encouraging healthcare providers to incorporate them into their diagnostic and treatment protocols.

Personalized medicine trends

The BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market is experiencing a significant boost due to the increasing adoption of personalized medicine trends. Personalized medicine, also known as precision medicine, is a healthcare approach that tailors medical care to the individual characteristics of each patient. In the context of heart-related conditions, this approach relies on precise diagnostic tools such as BNP and NT-proBNP markers to offer more targeted and effective treatments.

BNP and NT-proBNP play a vital role in the era of personalized medicine for several reasons: Personalized medicine seeks to identify an individual's unique risk factors and genetic predispositions. BNP and NT-proBNP testing provide essential information on a patient's cardiac health status. Elevated levels of these biomarkers can signify a higher risk of cardiovascular events, allowing healthcare providers to implement preventive strategies for high-risk individuals. In the context of heart failure, distinguishing it from other respiratory or cardiac conditions is crucial. BNP and NT-proBNP levels are highly specific to heart failure. Accurate diagnosis is the first step in personalized medicine, enabling the selection of the most suitable treatment options based on the patient's condition.

Once a patient's heart condition is accurately diagnosed, personalized medicine considers factors such as the patient's age, genetic profile, comorbidities, and lifestyle. BNP and NT-proBNP markers help guide treatment decisions. Physicians can choose medications, interventions, and therapies that are most likely to be effective, minimizing adverse effects and optimizing outcomes. The ongoing monitoring of a patient's cardiac health is integral to personalized medicine. BNP and NT-proBNP levels are monitored to assess the patient's response to treatment. If these biomarkers remain elevated or increase, healthcare providers can promptly adjust the treatment plan to better suit the patient's evolving needs.

Personalized medicine aims to predict a patient's likely response to treatment and their long-term prognosis. BNP and NT-proBNP levels serve as valuable prognostic tools, helping healthcare providers anticipate the patient's future health trajectory. This enables timely interventions and adjustments to improve the patient's quality of life and overall outcomes. As personalized medicine continues to gain prominence in healthcare, the demand for precise and individualized diagnostic tools like BNP and NT-proBNP is set to increase. Healthcare providers are increasingly incorporating these markers into their diagnostic and treatment protocols, allowing them to offer more effective and patient-centered care.

Key Market Challenges

Cost constraints in healthcare systems

Cost constraints in healthcare systems are driving the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market by emphasizing the need for cost-effective diagnostics. Healthcare providers and payers seek efficient ways to diagnose and manage cardiovascular diseases, given the economic pressures on the healthcare system. BNP and NT-proBNP testing, while essential for accurate cardiac assessments, are becoming more accessible and affordable. Market players are focusing on developing economical diagnostic solutions, including point-of-care devices, to address these constraints. This cost-conscious approach ensures that essential cardiac diagnostics are more widely available, contributing to the market's growth and relevance in a healthcare landscape driven by financial sustainability.

Competition from alternative diagnostic methods

Competition from alternative diagnostic methods is a driving force behind the growth of the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market. As the healthcare industry witnesses continuous innovation, alternative cardiac diagnostic techniques and markers emerge. In response, companies in the BNP and NT-proBNP market strive to maintain their competitive edge by enhancing their assays, improving accuracy, and streamlining testing processes. This competition spurs innovation, fosters the development of more efficient and cost-effective diagnostic solutions, and ultimately benefits patients by ensuring a broader array of diagnostic tools and options for cardiac assessment. It encourages continuous advancement within the BNP and NT-proBNP market to stay relevant and valuable in a dynamic healthcare landscape.

Variability in test results

Variability in test results within the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market serves as a catalyst for growth. This challenge highlights the need for more precise and standardized testing methodologies. To address this, companies invest in research and development to enhance the accuracy and consistency of their BNP and NT-proBNP assays. The demand for more reliable tests, with reduced variability, drives innovation, leading to the development of high-sensitivity assays and advanced diagnostic technologies. Healthcare providers and clinicians seek dependable results to make critical treatment decisions, and as the market responds to this demand, it experiences sustained growth and expansion.

Regulatory compliance and quality standards

Regulatory compliance and adherence to quality standards play a crucial role in driving the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market. Stricter regulations ensure that diagnostic tests meet rigorous safety and efficacy requirements, instilling confidence in healthcare providers and patients. The stringent oversight fosters innovation, as companies invest in research and development to meet these standards. Moreover, adherence to quality standards enhances the reliability and accuracy of BNP and NT-proBNP tests, making them indispensable tools in clinical practice. This regulatory support not only encourages market growth but also bolsters the credibility and trust associated with these cardiac biomarkers.

Key Market Trends

Telemedicine and remote monitoring

Telemedicine and remote monitoring have emerged as pivotal trends in the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market. These technologies enable healthcare providers to remotely assess and monitor patients' cardiac health, reducing the need for frequent in-person visits. BNP and NT-proBNP testing, with their ability to provide valuable cardiac insights, are integrated into these remote monitoring systems. As telemedicine gains traction, the demand for accurate and real-time cardiac diagnostics becomes more critical. BNP and NT-proBNP testing facilitate continuous patient monitoring and timely intervention, making them indispensable components in the shift towards more patient-centric and efficient healthcare delivery. This trend further drives the growth of the BNP and NT-proBNP market.

High-sensitivity assays development

High-sensitivity assays development is a notable trend in the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market. These assays offer enhanced precision and lower detection limits, allowing for the measurement of even trace amounts of these biomarkers. High-sensitivity assays are particularly valuable in early disease detection and risk stratification, as they can identify cardiac issues at their nascent stages. This trend reflects the industry's commitment to improving diagnostic accuracy and clinical outcomes, reinforcing the importance of BNP and NT-proBNP markers in cardiology. The development of high-sensitivity assays further solidifies the position of these biomarkers in the forefront of cardiac diagnostics and patient care.

Integration of AI and machine learning

The integration of AI (Artificial Intelligence) and machine learning is a compelling trend in the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market. These advanced technologies have the potential to revolutionize cardiac diagnostics by enhancing data analysis and interpretation. AI-driven algorithms can rapidly process vast amounts of patient data, including BNP and NT-proBNP levels, to assist healthcare providers in making more accurate diagnoses and treatment decisions. Machine learning models can predict patient outcomes and identify patterns that might be missed through traditional methods. This trend not only improves the efficiency and accuracy of testing but also positions BNP and NT-proBNP markers at the forefront of cutting-edge, data-driven healthcare solutions.

Segmental Insights

Location of Testing Insights

Based on the location of testing, Point of care testing has emerged as the fastest growing segment in the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market, revolutionizing cardiac diagnostics. These portable, rapid, and user-friendly POCT devices enable healthcare professionals to conduct BNP and NT-proBNP testing at the patient's bedside or in primary care settings, ensuring quicker results and immediate clinical decision-making. POCT is especially valuable in emergency departments and critical care situations, expediting the identification and management of cardiac conditions. This trend aligns with the growing emphasis on timely and convenient healthcare solutions, making BNP and NT-proBNP testing more accessible, reducing diagnostic turnaround times, and enhancing patient care in various clinical settings.

Application Insights

Based on application, Myocardial Infarction, commonly known as a heart attack, has emerged as the dominating segment of the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market. These cardiac biomarkers play a pivotal role in the diagnosis and management of MI. Elevated BNP and NT-proBNP levels are indicative of cardiac stress, making them crucial in the early identification of MI. Rapid and accurate MI diagnosis is essential for timely interventions, reducing the risk of life-threatening complications. With the global burden of MI increasing, the demand for these biomarkers as reliable diagnostic tools in emergency settings continues to rise, cementing their significance in the field of cardiology.

Regional Insights

North America has dominated the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market in 2023 for several reasons. The region has a well-established and technologically advanced healthcare infrastructure, fostering the early adoption of cutting-edge diagnostic tools like BNP and NT-proBNP assays. The prevalence of cardiovascular diseases in North America is notably high, driving the demand for accurate and timely cardiac assessments. The presence of major market players and research institutions dedicated to cardiac health propels innovation. Lastly, strong regulatory frameworks and clinical guidelines support the use of these biomarkers, solidifying North America's dominant position in the BNP and NT-proBNP market.

Key Market Players

Specim, Spectral Imaging Ltd

Gentian Diagnostics ASA

Siemens AG

PerkinElmer Inc

Biomerieux SA

Quidel Corporation

Bio-Rad Laboratories, Inc.

F. Hoffman-La Roche Ltd

BHR Pharmaceuticals Ltd.

Xiamen Biotime Biotechnology Co., Ltd.

Report Scope:

In this report, the Global BNP And NTproBNP Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

BNP And NTproBNP Market, By Type:

    Brain Natriuretic Peptide NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide)

BNP And NTproBNP Market, By Location of Testing:

    Point Of Care Testing Laboratory Testing

BNP And NTproBNP Market, By Application:

    Myocardial Infarction Congestive Heart Failure Acute Coronary Syndrome (ACS) Others

BNP And NTproBNP Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global BNP And NTproBNP Market.

Available Customizations:

Global BNP And NTproBNP Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global BNP And NTproBNP Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type (BNP (Brain Natriuretic Peptide), NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide))
    • 4.2.2. By Location of Testing (Point Of Care Testing, Laboratory Testing)
    • 4.2.3. By Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2023)
  • 4.3. Market Map
    • 4.3.1. By Type
    • 4.3.2. By Location of Testing
    • 4.3.3. By Application
    • 4.3.4. By Region

5. Asia Pacific BNP And NTproBNP Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Location of Testing
    • 5.2.3. By Application
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China BNP And NTproBNP Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Type
        • 5.3.1.2.2. By Location of Testing
        • 5.3.1.2.3. By Application
    • 5.3.2. India BNP And NTproBNP Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Type
        • 5.3.2.2.2. By Location of Testing
        • 5.3.2.2.3. By Application
    • 5.3.3. Australia BNP And NTproBNP Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Type
        • 5.3.3.2.2. By Location of Testing
        • 5.3.3.2.3. By Application
    • 5.3.4. Japan BNP And NTproBNP Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Type
        • 5.3.4.2.2. By Location of Testing
        • 5.3.4.2.3. By Application
    • 5.3.5. South Korea BNP And NTproBNP Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Type
        • 5.3.5.2.2. By Location of Testing
        • 5.3.5.2.3. By Application

6. Europe BNP And NTproBNP Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Location of Testing
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France BNP And NTproBNP Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Location of Testing
        • 6.3.1.2.3. By Application
    • 6.3.2. Germany BNP And NTproBNP Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Location of Testing
        • 6.3.2.2.3. By Application
    • 6.3.3. Spain BNP And NTproBNP Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Location of Testing
        • 6.3.3.2.3. By Application
    • 6.3.4. Italy BNP And NTproBNP Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Location of Testing
        • 6.3.4.2.3. By Application
    • 6.3.5. United Kingdom BNP And NTproBNP Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Location of Testing
        • 6.3.5.2.3. By Application

7. North America BNP And NTproBNP Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Location of Testing
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States BNP And NTproBNP Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Location of Testing
        • 7.3.1.2.3. By Application
    • 7.3.2. Mexico BNP And NTproBNP Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Location of Testing
        • 7.3.2.2.3. By Application
    • 7.3.3. Canada BNP And NTproBNP Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Location of Testing
        • 7.3.3.2.3. By Application

8. South America BNP And NTproBNP Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Location of Testing
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil BNP And NTproBNP Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Location of Testing
        • 8.3.1.2.3. By Application
    • 8.3.2. Argentina BNP And NTproBNP Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Location of Testing
        • 8.3.2.2.3. By Application
    • 8.3.3. Colombia BNP And NTproBNP Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Location of Testing
        • 8.3.3.2.3. By Application

9. Middle East and Africa BNP And NTproBNP Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Location of Testing
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa BNP And NTproBNP Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Location of Testing
        • 9.3.1.2.3. By Application
    • 9.3.2. Saudi Arabia BNP And NTproBNP Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Location of Testing
        • 9.3.2.2.3. By Application
    • 9.3.3. UAE BNP And NTproBNP Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Location of Testing
        • 9.3.3.2.3. By Application

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global BNP And NTproBNP Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Specim, Spectral Imaging Ltd
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. Gentian Diagnostics ASA
  • 14.3. Siemens AG
  • 14.4. PerkinElmer Inc
  • 14.5. Biomerieux SA
  • 14.6. Quidel Corporation
  • 14.7. Bio-Rad Laboratories, Inc.
  • 14.8. F. Hoffman-La Roche Ltd
  • 14.9. BHR Pharmaceuticals Ltd.
  • 14.10. Xiamen Biotime Biotechnology Co., Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer